The endogenous cannabinoid anandamide (arachidonylethanolamide) produces vasorelaxation in different vascular beds. In the present study, we found that anandamide and a metabolically stable analog, methanandamide, produced dose-dependent (10 nM-10 M) vasorelaxation of ϳ80% in a rabbit aortic ring preparation in an endothelium-dependent manner. Non-endothelium-dependent vasorelaxation was observed to be a maximum of 20-22% at Ͼ10 M methanandamide. The efficacious CB 1 receptor analogs desacetyllevonantradol (10 M) and WIN55212-2 (10 M) failed to produce vasorelaxation; however, the endotheliumdependent vasorelaxation evoked by methanandamide was partially (75%) blocked by the CB 1 receptor antagonist SR141716A. The VR 1 vanilloid receptor antagonist capsazepine or the calcitonin gene-related peptide (CGRP) antagonist CGRP-(8-37) partially attenuated (25%) the vasorelaxation in endothelium-intact preparations and greatly reduced the response in endothelium-denuded preparations. Pretreatment of aortic rings with N G -nitro-L-arginine methyl ester completely blocked the methanandamide-, capsaicin-, and CGRP-induced vasorelaxation. Pretreatment of aortic rings with pertussis toxin attenuated the methanandamideinduced vasorelaxation in endothelium-intact aortic rings, indicating the involvement of G i/o proteins in the vasorelaxation; however, pertussis toxin treatment failed to block the endothelium-independent response. Thus, in the rabbit aorta, methanandamide-induced vasorelaxation exhibits two components: 1) in endothelium-intact rings, an SR141716A-sensitive, non-CB 1 receptor component that requires pertussis toxin-sensitive G proteins and nitric oxide (NO) production; and 2) in endothelium-denuded rings, a component that is mediated by VR1 vanilloid receptors and possibly by the subsequent release of CGRP that requires NO production but is independent of pertussis toxin-sensitive G proteins. cannabinoid receptors; vanilloid receptors; pertussis toxin; endothelium; nitric oxide CANNABINOID DRUGS are known to produce profound cardiovascular effects in humans and animals (2, 13, 15). Recent findings have demonstrated that some cardiovascular effects are produced by the eicosanoid anandamide (arachidonylethanolamide) and its analogs in various animal models, including conscious or anesthetized normotensive or spontaneously hypertensive rats (19, 20, 39) . In anesthetized rats, anandamide produced sequential, triphasic changes consisting of a transient bradycardia and hypotension, followed by a brief pressure increase and finally a relatively long-lasting depressor effect (38). The anandamide-induced prolonged hypotension was blocked by the CB 1 antagonist SR141716A (19, 20, 38) , suggesting that this effect of anandamide is mediated by the CB 1 receptor. The failure of anandamide and other potent cannabinoid receptor agonists to elicit the longlasting depressor effect in CB 1 knockout (Ϫ/Ϫ) mice provides further support for the involvement of the CB 1 receptor in this component of the response (18). Recent studies have suggested that anandamide and other cannabinoid agonists induce hypotension by presynaptic inhibition of norepinephrine (NE) release (23, 26, 39) in a SR141716A-sensitive manner (16, 23). These findings suggest the involvement of a neuronal CB 1 receptor signaling mechanism for certain cardiovascular effects of cannabinoid drugs. In contrast, SR141716A failed to attenuate the anandamide-induced activation of both initial bradycardia and subsequent pressure changes (38), suggesting that this particular component of the anandamide response may not involve the CB 1 receptor.
lar effects are produced by the eicosanoid anandamide (arachidonylethanolamide) and its analogs in various animal models, including conscious or anesthetized normotensive or spontaneously hypertensive rats (19, 20, 39) . In anesthetized rats, anandamide produced sequential, triphasic changes consisting of a transient bradycardia and hypotension, followed by a brief pressure increase and finally a relatively long-lasting depressor effect (38) . The anandamide-induced prolonged hypotension was blocked by the CB 1 antagonist SR141716A (19, 20, 38) , suggesting that this effect of anandamide is mediated by the CB 1 receptor. The failure of anandamide and other potent cannabinoid receptor agonists to elicit the longlasting depressor effect in CB 1 knockout (Ϫ/Ϫ) mice provides further support for the involvement of the CB 1 receptor in this component of the response (18) . Recent studies have suggested that anandamide and other cannabinoid agonists induce hypotension by presynaptic inhibition of norepinephrine (NE) release (23, 26, 39) in a SR141716A-sensitive manner (16, 23) . These findings suggest the involvement of a neuronal CB 1 receptor signaling mechanism for certain cardiovascular effects of cannabinoid drugs. In contrast, SR141716A failed to attenuate the anandamide-induced activation of both initial bradycardia and subsequent pressure changes (38) , suggesting that this particular component of the anandamide response may not involve the CB 1 receptor.
In addition to the effect on blood pressure, anandamide evoked vascular smooth muscle relaxation in various endothelium-intact and -denuded arterial preparations (for a review, see Ref. 41) . A SR141716A-sensitive, anandamide-induced vasorelaxation that does not respond to classical cannabinoid receptor agonists has been demonstrated by Wagner et al. (40, 41) , who proposed that a novel "anandamide receptor" was involved. However, this interpretation is not compatible with the findings of Pratt et al. (31) , who proposed that metabolism of anandamide to other eicosanoid products could be responsible for the vasorelaxation.
More recently, the vasorelaxing effects of anandamide (but not classical CB 1 agonists) in isolated rat hepatic, rat mesenteric, and guinea pig basilar arterial preparations have been explained by a noncannabinoid receptor mechanism involving the VR 1 vanilloid receptor (46) . In that study, anandamide-induced vasodilation was shown to be blocked either by the VR 1 antagonist capsazepine or the calcitonin gene-related peptide (CGRP) antagonist CGRP-(8-37) but not by SR141716A (46) . Results of these studies suggest that anandamide activates VR 1 receptors on the perivascular sensory neurons to release CGRP, which would then evoke vascular relaxation.
In the present study, we found that in rabbit arterial ring preparations, methanandamide produced vasorelaxation by two different signal transduction pathways. The major component of the relaxation was attributed to a SR141716A-sensitive non-CB 1 receptormediated activation of pertussis toxin-sensitive G proteins and involves endothelium-derived nitric oxide (NO) for vasorelaxation. The other component was due to anandamide-activated VR 1 receptors and CGRPmediated vasorelaxation, which involves non-endothelium-derived NO and is independent of pertussis toxinsensitive G proteins.
MATERIALS AND METHODS
Reagents. Methanandamide was purchased from Research Biochemicals (Natick, MA). Desacetyllevonantradol (DALN) was a gift from Pfizer (Groton, CT). WIN55212-2 was obtained from Sigma-RBI (St. Louis, MO). SR141716A was purchased from BioMol (Plymouth Meeting, CA). NE, indomethacin, N G -nitro-L-arginine methyl ester (L-NAME), acetylcholine chloride (ACh), CGRP, CGRP-(8-37), anandamide, and arachidonic acid were obtained from Sigma. Capsaicin and capsazepine were purchased from Tocris (Ballwin, MO). Glyceryl trinitrate (GTN; Nitrostat, 0.4-mg tablets) was a product of Parke-Davis (Ann Arbor, MI). All other chemicals used were of the highest analytic grade and were obtained from Sigma.
Tissue preparation. Male New Zealand White rabbits (2.5-3.5 kg) were anesthetized with ketamine (3 mg/kg im) plus xylazine (1 mg/kg im), followed by pentobarbital sodium (15 mg/kg iv). A cannula was placed into the carotid artery, and heparin (200 U/kg iv) was administered. After 10 min, the animals were exsanguinated. The abdomen was opened by a midline incision, and the aorta was carefully excised and placed in ice-cold Krebs-Ringer bicarbonate (KRB) buffer [containing (in mM) 118.3 NaCl, 4.7 KCl, 2.5 CaCl 2, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 0.026 Na-EDTA, and 11.1 glucose; pH 7.4] at 4°C. All connective and perivascular adipose tissues were removed, with caution being taken not to disrupt the endothelial cell lining. Aortas were then refrigerated in KRB buffer for use either the same or the following day. Storage for 24 h did not affect endothelium-dependent vasomotor responses. Transverse vascular rings 3-4 mm long were prepared from the aorta and suspended from an isometric force transducer (Grass FT .03) according to methods previously described (27, 28) . Briefly, the rings were mounted horizontally between an L-shaped fixed stainless steel rod and a freely moving stainless steel triangle attached to an isometric force transducer by a S hook in a 25-ml jacketed glass organ bath. Rings were bathed in 20 ml KRB buffer (37°C) and continuously aerated with 95% O 2-5% CO2. The KRB buffer also contained indomethacin (10 M) to inhibit cyclooxygenase activity. The rings were then gradually stretched over a period of 45-60 min until the optimum basal tension (2 g, as predetermined from tension-force studies) was achieved. The tissues were washed with 20 ml of fresh KRB buffer every 15-20 min. After an initial equilibration period of 20 min, rings were contracted with KCl (60 mM) to stabilize and enhance subsequent submaximal contraction (28) . The tissues were washed with fresh KRB buffer to remove KCl, and, thereafter, submaximal tone (60-70%) was induced in the rings with NE (100 nM). After the submaximal NE-induced contraction of the rings, the test compounds were added into the incubation medium to achieve the final indicated concentrations in a cumulative manner. When aortic rings were treated with SR141716A, capsazepine, or CGRP-(8-37), these drugs were included for 30 min at 37°C, and anandamide-or methanandamide-induced relaxation was then determined. Data are presented as percent relaxation, calculated as the percentage of the difference between the NE-contracted tone and the basal tone. After each series of additions, the rings were washed several times with fresh KRB buffer and allowed to reequilibrate for 20-30 min.
Measurement of vasorelaxing effects of drugs under endothelium-denuded conditions. For the endothelium-denuded preparation, the endothelium was removed by rubbing the intimal surface of the rings with the roughened shaft of a 23-gauge needle (27, 28) . The successful removal of the endothelium was ascertained by the absence or markedly reduced (90%) relaxation produced in response to ACh. These same rings were also tested with the endothelium-independent relaxing agent GTN to assure that the lost response to ACh was due to the loss of the endothelium and not due to damage to the underlying smooth muscle structure. After the removal of the endothelium, the rings were allowed to reequilibrate to basal tension for 30-45 min in KRB buffer, after which the vasorelaxing effects of the indicated drugs were determined.
Treatment with pertussis toxin. To determine the involvement of G i/o proteins in vasorelaxation, rabbit aortic rings were treated with pertussis toxin (250 ng/ml) or its vehicle for 2 h at 37°C (26) . After the incubation period, the rings were washed with KRB buffer and submaximally contracted with NE, and vasomotor responses to agonists and/or antagonists were determined. Experiments were performed such that drug-induced vasorelaxation was determined both before and after pertussis toxin treatment to compare the responses in a paired manner.
Treatment with L-NAME. To determine the role of NO in agonist-induced vasorelaxation, endothelium-intact or -denuded rings were pretreated with L-NAME (30 M for 45 min at 37°C). The rings were then washed with KRB buffer, allowed to equilibrate for an additional 20 min, and contracted with NE, and vasomotor responses to the test compounds were measured. Agonist-induced vasorelaxation was determined both before and after L-NAME treatment in the same rings to make paired comparisons.
Data analysis. All values are expressed as means Ϯ SE of multiple, separate experiments. Data were analyzed by ANOVA, followed by a Bonferroni post hoc test. The log dose-response curves were analyzed by nonlinear regression analysis of a sigmoidal curve to determine concentrations at half-maximal response and the slope factors (Graphpad Inplot).
sponse in endothelium-intact rings was ϳ60% relaxation (Fig. 1A) . Methanandamide, a metabolically stable analog of anandamide (1), also produced a concentration-dependent relaxation of aortic rings (Fig. 1,  A and B) . No significant differences were observed when relaxations produced by anandamide and methanandamide were compared, suggesting that anandamide degradation is not prevalent under these experimental conditions. In endothelium-intact aortic rings, the maximum relaxation of ϳ80% was obtained with 20 M methanandamide and the EC 50 was 0.6 M (Fig. 2B ). The onset of relaxation began within 15 s after the addition of methanandamide to the KRB buffer.
The methanandamide-induced relaxation was markedly attenuated after mechanical denudation of the same ring (compare Fig. 1 , C with B; see also Figs. 3B, 4C, and 5B). The non-endothelial-dependent relaxation achieved a maximum of 18-20% at high concentrations of methanandamide (20 M). Anandamide-induced vasorelaxation was also abrogated (80-85%) after endothelial denudation (data not shown). To control for the integrity of the smooth muscle, addition of the NO donor GTN (0.1 M) to the endothelium-denuded ring produced almost complete relaxation (95-100%) (Fig.  1C) . No significant difference was observed in GTNinduced relaxation before or after endothelium denudation or with a higher concentration of GTN (1 M) (data not shown).
Chaytor and colleagues (7) reported that in rabbit superior mesenteric arterial preparations, gap junctions are involved in anandamide-induced endothelium-dependent relaxation because the response could be blocked by the gap junction inhibitor 18␣-glycerrhetinic acid and connexin43 mimetic peptide. We tested for a gap junction involvement in rabbit aortic ring preparations by preincubation of the rabbit aortic rings with the gap junction inhibitor 18␣-glycerrhetinic acid (50 M for 1 h). This treatment did not block the anandamide-or methanandamide-induced relaxation (data not shown). This suggests that anandamide/ methanandamide produced vasorelaxation in the rabbit aortic rings through a gap junction-independent mechanism and therefore does not involve transfer of small molecules between cells. A recent study by White and colleagues (44) reported that anandamide-induced vasorelaxation in rat coronary arteries was not affected by the gap junction inhibitor 18␣-glycerrhetinic acid.
Methanandamide produces vasorelaxation in a SR141716A-sensitive manner but not via the CB 1 receptor. To address the issue of whether the anandamide-induced vasorelaxation in rabbit aortic rings could be due to stimulation of the CB 1 receptor, we evaluated the vasoactivity of DALN and WIN55212-2, two potent and efficacious CB 1 receptor agonists of the cannabinoid and aminoalkylindole chemical classes. Neither the classical cannabinoid agonist DALN nor the aminoalkylindole WIN55212-2 were able to produce a significant relaxation of the endothelium-intact aortic rings at any of the concentrations tested (100 nM-10 M; Fig. 1A) . Additionally, the CB 1 agonists produced no response whether the endothelium was functionally intact or not (data not shown). Thus the anandamide and methanandamide response is not consistent with a CB 1 pharmacological profile.
To further address the hypothesis that anandamide and methanandamide-induced relaxation is mediated by the CB 1 receptor, studies were performed using the potent and selective CB 1 antagonist SR141716A. Anandamide and methanandamide produced relaxation in endothelium-intact aortic rings at all concentrations tested with EC 50 0.7 and 0.6 M, respectively (Fig. 2, A and B) . The anandamide response was reduced in the presence of 1 M SR141716A (Fig. 2A) . It was not possible to properly determine the EC 50 because of concerns about lack of solubility at high concentrations of anandamide. The methanandamide log concentration-response curve also underwent a rightward parallel shift (EC 50 ϭ 4.2 M) in the presence of 1 M SR141716A without any alteration in the maximum response, consistent with competitive antagonism (Fig. 2B) . When added to the incubation medium after methanandamide-induced relaxation, SR141716A partially reversed the response (data not shown). Higher concentrations of SR141716A were not used to induce a further antagonism because this drug has been reported to evoke miscellaneous cellular effects at a concentration Ͼ3 M (31, 43). The CB 2 cannabinoid receptor antagonist SR144528 did not block the anandamide-or methanandamide-induced vasorelaxation in the rabbit aortic ring preparation. This suggests that the anandamide-or methanandamide-induced response in rabbit aortic rings was not mediated through CB 2 cannabinoid receptors.
SR141716A did not alter ACh-induced relaxation under conditions identical to those used for the anandamide and methanandamide responses (Fig. 2C) , suggesting specificity of the antagonist for the anandamide-induced response. The endothelium-independent Fig. 4 . Effect of N G -nitro-L-arginine methyl ester (L-NAME) on methanandamide-and capsaicin-induced vasorelaxation of NE-contracted endothelium-intact (A) and endothelium-denuded rabbit aortic rings (B). C: effect of L-NAME on CGRP-induced vasorelaxation of endothelium-intact and endothelium-denuded rabbit aortic rings. Rings were pretreated with L-NAME (30 mM) or its vehicle (water) for 30 min before the contraction with NE, and methanandamide, capsaicin, or CGRP was then added at the indicated cumulative final concentrations. Data are presented as means Ϯ SE of the percent relaxation from 4 separate aortic rings from different rabbits. The percent relaxation was significantly different (* P Ͻ 0.02 and ϩϩP Ͻ 0.05) between the absence and presence of L-NAME. Fig. 5 . Effects of pertussis toxin (PTX) on methanandamide-induced vasorelaxation of NE-contracted endothelium-intact (A) and endothelium-denuded rabbit aortic rings (B). Rings were pretreated with PTX (250 ng/ml) for 2 h at 37 o C, and methanandamide was then added at the indicated cumulative final concentrations. Data are presented as means Ϯ SE of the percent relaxation from 3 separate aortic rings from different rabbits. A: methanandamide-induced percent relaxation was significantly different (* P Ͻ 0.02) between vehicle-and PTX-treated endothelium-intact aortic rings at all the concentrations of methanandamide. B: no significant differences were observed between vehicle-and PTX-treated aortic rings after endothelium denudation. component of the methanandamide-induced relaxation, which was observed in denuded rings, was not attenuated in the presence of SR141716A (data not shown). Furthermore, SR141716A did not affect the vasorelaxation evoked by glyceryl trinitrate (data not shown), indicating that the antagonism is not at the level of the smooth muscle.
VR 1 receptor and CGRP antagonists block methanandamide-induced endothelium-independent relaxation. The role of vascular innervation on the methanandamide-induced relaxation of rabbit aortic rings was addressed by examining the effects of VR 1 receptor-dependent neuromediator release. Pretreatment (30 min at 37°C) of endothelium-intact rabbit aortic rings with either the VR 1 antagonist capsazepine (3 M) or the CGRP receptor antagonist CGRP-(8-37) (2 M) partially blocked (15-20%) methanandamide-induced relaxation (Fig. 3A) . In endothelium-denuded rings, pretreatment with both capsazepine and CGRP-(8-37) totally blocked the relaxation evoked by 20 M methanandamide (Fig. 3B) . These data suggest that the endothelium-independent component of the methanandamide-induced relaxation can be attributed to the activation of VR 1 receptors known to be present on the primary sensory neurons embedded in the smooth muscle cell layer in the aortic vessel wall (46) . Furthermore, these results suggest that the methanandamidestimulated VR 1 receptor evokes vasorelaxation primarily by the release of the vasodilator CGRP from the prearterial nerve endings.
The methanandamide-induced, endothelium-independent vasorelaxation is only a small fraction of the vasorelaxation that can be produced by VR 1 receptors in the rabbit aortic ring preparation. Capsaicin and CGRP (10 M) produced robust relaxation of endothelium-intact rabbit aortic rings [70% (Fig. 4A) and 60% (Fig. 4C) , respectively]. This occurs in a concentrationdependent manner with EC 50 of 1 and 0.3 M, respectively (data not shown). Of importance, the capsaicinand CGRP-mediated relaxation in endothelium-denuded rings was significantly less than that observed with endothelium-intact rings (25% and 15%, respectively; Fig. 4 ). This shows that capsaicin-and CGRPevoked relaxation in the rabbit aortic ring preparation exhibits an endothelium-dependent component that is not related to the response that was produced by methanandamide.
L-NAME blocks both methanandamide-and capsaicin-induced relaxation. Pretreatment (30 min at 37°C) of endothelial intact rings with the NO synthase (NOS) inhibitor L-NAME (30 M) almost completely blocked methanandamide-and capsaicin-induced relaxation in endothelium-intact (Fig. 4A) and -denuded (Fig. 4B) rabbit aortic rings. CGRP-mediated relaxation was also significantly blocked after L-NAME treatment in endothelium-intact and -denuded rings (Fig. 4C) . These results indicate that methanandamide, capsaicin, and CGRP produced vasorelaxation via a NOmediated mechanism.
Pertussis toxin treatment blocks methanandamideinduced relaxation in endothelium-intact rings. The CB 1 and CB 2 cannabinoid receptors are coupled to signal transduction pathways that are mediated via the pertussis toxin-sensitive G i/o proteins (for a review, see Ref. 14) . We performed a study to determine whether the methanandamide-induced vasorelaxation is mediated via G i/o proteins. Treatment of rabbit aortic rings with pertussis toxin (250 ng/ml for 2 h at 37°C) significantly blocked the methanandamide-induced relaxation in endothelium-intact rings (Fig. 5A) . However, in endothelial-denuded rings, pertussis toxin treatment had no effect on methanandamide-induced relaxation (Fig. 5B) . Pertussis toxin treatment also blocked the anandamide-induced vasorelaxation in endothelium-intact rings (data not shown). The methanandamide-induced relaxation in pertussis toxintreated endothelium-intact rings is equivalent in magnitude to that produced in endothelium-denuded rings (20%). This observation suggests that the endothelium-dependent component of the methanandamide-induced relaxation in the rabbit aorta is mediated by a pertussis toxin-sensitive G protein, whereas the endothelium-independent, VR 1 -mediated component of the relaxation is not.
DISCUSSION
The present study demonstrates that anandamide and methanandamide can activate at least two different pathways to produce vasorelaxation in the rabbit aortic ring model. When taken together, the data indicate that the endothelium-dependent, SR141716A-sensitive component of anandamide-or methanandamideinduced relaxation in the rabbit aorta is regulated by a pertussis toxin-sensitive G protein. The results of the present study have also provided evidence in support of the dual involvement of pertussis toxin-sensitive G proteins and NO in the vasoregulatory effects of anandamide and methanandamide. In contrast, the endothelium-independent, VR 1 -mediated component of the relaxation is G i/o protein independent. This represents the first report of the involvement of pertussis toxinsensitive G proteins with the endothelium-dependent component of anandamide/methanandamide relaxation and is important because it implicates a G protein-coupled receptor in the endothelium-dependent response.
The anandamide-induced relaxation was found to be endothelium dependent in bovine coronary arteries (31) but not in rat mesenteric (42) , coronary (44) , and hepatic (45) arteries. The finding of CB 1 mRNA and protein in rat and human vascular endothelial cells (9, 21) allows for the possible involvement of CB 1 receptors in vasoregulation at the level of endothelial cells. However, mediation by the CB 1 receptor in the present studies is made untenable by the observation that very potent and efficacious cannabinoid receptor agonists DALN and WIN55212-2 failed to evoke relaxation of the rabbit aortic ring preparation. Antagonism of the anandamide-or methanandamide-evoked vasorelax-ation response by SR141716A is in agreement with previous findings in rat coronary (33) and mesenteric (34) arteries. In the present studies, a greater concentration of SR141716A (1 M) was necessary to shift the concentration-response curve eightfold for methanandamide in the aortic ring relaxation compared with a response believed to be mediated via the CB 1 receptor. For example, for the inhibition by WIN55212-2 of the guinea pig myenteric plexus longitudinal muscle twitch response, a shift of one order of magnitude could be produced by SR141716A at a concentration of 100 nM (8) . Similar to the observations made in this study, anandamide-induced relaxation in rat coronary arteries was attenuated by SR141716A at a relatively higher concentration (3 M) (44) . These findings suggest that a novel noncannabinoid receptor that nevertheless exhibits sensitivity to SR141716A exists in this preparation. Our studies support the existence of a SR141716A-sensitive "anandamide" receptor, which has been previously proposed by Kunos and colleagues (18, 40) .
Anandamide has previously been proposed to be an endothelium-derived hyperpolarizing factor (EDHF) (32) . Blockade of carbachol-and anandamide-mediated relaxation by SR141716A in isolated, buffer-perfused rat mesenteric and coronary vasculature as well as in mesenteric arterial segments implicated the CB 1 receptor in these events (32) (33) (34) . Unlike our experiments, in those studies, anandamide-or carbacholinduced relaxation was measured in the presence of L-NAME (300 M) and indomethacin (10 M) to detect a non-NO, EDHF response. However, these findings were not confirmed by other laboratories (5, 30) . The "EDHF"-like response of anandamide measured in the presence of L-NAME was found to be pertussis toxin sensitive (42) . Results of our study suggest that anandamide-induced vasorelaxation involves a pertussis toxin-sensitive G protein but that the final mediator is NO, obviating the notion of anandamide as an EDHF. Furthermore, our finding that SR141716A fails to alter the response to ACh but exhibits a competitive inhibition for methanandamide would eliminate the possibility that the ACh response occurred via the release of endogenously synthesized anandamide in the rabbit aorta.
Anandamide-derived arachidonic acid released by the action of fatty acid aminohydrolase and subsequently formed eicosatrienoic acid derivatives was held responsible for the vasodilatory action of anandamide in studies by Pratt et al. (31) . The involvement of eicosanoid metabolites can be ruled out in the present study for the following reasons: 1) anandamide and its metabolically stable analog methanandamide produced an identical profile of relaxation; 2) arachidonic acid itself did not produce any response in the rabbit aortic ring preparation (data not shown); 3) the epoxyeicosatrienoic acid inhibitor 17-octadecanoic acid did not alter anandamide-or methanandamide-induced relaxation (data not shown); and 4) participation of cyclooxygenase products in methanandamide-induced vasorelaxation can be ruled out because indomethacin was used in all the experiments reported in the present study.
Zygmunt and colleagues (46) demonstrated that in isolated rat hepatic, rat mesenteric, and guinea pig basilar arterial preparations, anandamide-induced relaxation was almost completely blocked by the VR 1 vanilloid receptor antagonist capsazepine but not by SR141716A. They suggested that the VR 1 -mediated release of neuromediators is responsible for the anandamide-evoked vasorelaxation (46) . The response observed by Zygmunt et al. (46) appears to be comparable to that which we observed in the endothelium-denuded rings. This is consistent with a mechanism by which methanandamide activates the VR 1 receptor to cause vasorelaxation via CGRP. In mesenteric arteries of rabbits (25) , splenic, gastric, and hepatic arteries of rats (4), splenic arteries of pigs (29) , cerebral arteries of cats (10, 35) , and pulmonary arteries of guinea pigs (22) and humans (24) , CGRP-induced vasorelaxation is endothelium independent. The relaxation that we observed in the rabbit aortic ring preparation was not pertussis toxin sensitive, which would be consistent with the actions of CGRP occurring via a non-G i/o subtype of G proteins (6) .
The significant attenuation by L-NAME of both components of the methanandamide-evoked vasorelaxation, as well as the capsaicin-and CGRP-evoked vasorelaxation, suggests the involvement of NO in both endothelium-dependent and -independent vasorelaxation. Anandamide has been reported to activate endothelial NOS in the human saphenous vein, and this effect was blocked by SR141716A (37) . Although there is no consensus regarding the role of NO in capsaicin and CGRP-induced vasorelaxation, evidence suggests that capsaicin causes the release of CGRP, which in turn activates endothelial NOS activity to produce NO to evoke vasodilation (11, 12) . In vascular smooth muscle cells (36) and in the rat thoracic aorta (12) , CGRP increased NOS activity via a cAMP-dependent pathway. Results from other laboratories suggest that NO is involved in the capsaicin-stimulated release of CGRP (3) .
In summary, the present findings indicate that anandamide and methanandamide induce vasorelaxation in the rabbit aorta by the activation of a non-CB 1 "anandamide" receptor coupled to G i/o protein(s) via an endothelium-dependent mechanism requiring NO synthesis. To the best of our knowledge, this is the first report of the involvement of a pertussis toxin-sensitive G protein in methanandamide-induced vasodilation. A less prominent endothelium-independent component of the vasorelaxation results from anandamide's stimulation of the VR 1 receptor and subsequent release of the vasodilator CGRP.
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